核受体:肝病中的病理生理机制与药物靶点
核受体(NRs)是肝脏发育和功能所需的配体依赖性转录因子,已成为多种肝病的药物靶点。但肝功能障碍与衰竭伴随肝细胞身份丢失,表现为NR表达和活性缺陷,这可能部分解释为何多种NR药理调节剂在代谢功能障碍相关脂肪性肝病(MASLD)等晚期疾病中改善肝功能的效果不足。本文综述肝脏NR领域最新进展,讨论多组学方法对理解NR在转录调控网络、肝脏细胞间对话和器官间交互中作用的价值,并探讨同时靶向多个NR的新型治疗策略的潜在益处及考虑性别和疾病阶段等个体参数的必要性。
要点
- 核受体是肝脏发育和功能所需的配体依赖性转录因子,已成为多种肝病的药物靶点。
- 肝功能障碍与衰竭伴随肝细胞身份丢失,表现为NR表达和活性缺陷。
- 同时靶向多个NR的策略可能重新激活肝脏NR网络、恢复肝细胞身份并影响细胞间和器官间交互。
核心结论
- 肝功能障碍和衰竭与肝细胞身份丢失相关,其特征是NR表达和活性缺陷,这可能部分解释为何多种NR药理调节剂在MASLD等晚期疾病中改善肝功能的效果不足。
- 同时靶向多个NR的新型治疗策略可能不仅重新激活肝脏NR网络和恢复肝细胞身份,还可影响对控制肝功能至关重要的细胞间和器官间交互。
- 开发基于NR的临床策略时需要考虑性别和疾病阶段等个体参数。
研究设计与样本
- 本文为视角文章,综述肝脏核受体领域的最新进展。
主要发现
- 多组学方法有助于理解NR在复杂转录调控网络的分子组织、肝脏细胞间对话和器官间交互中的作用。
- 多种药理学NR调节剂在MASLD等晚期疾病中改善肝功能的效果不足。
- 肝功能障碍和衰竭与肝细胞身份丢失相关,表现为NR表达和活性缺陷。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nuclear receptors (NRs) are ligand-dependent transcription factors required for liver development and function. As a consequence, NRs have emerged as attractive drug targets in a wide range of liver diseases. However, liver dysfunction and failure are linked to loss of hepatocyte identity characterised by deficient NR expression and activities. This might at least partly explain why several pharmacological NR modulators have proven insufficiently efficient to improve liver functionality in advanced stages of diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD). In this perspective, we review the most recent advances in the hepatic NR field and discuss the contribution of multiomic approaches to our understanding of their role in the molecular organisation of an intricated transcriptional regulatory network, as well as in liver intercellular dialogues and interorgan cross-talks. We discuss the potential benefit of novel therapeutic approaches simultaneously targeting multiple NRs, which would not only reactivate the hepatic NR network and restore hepatocyte identity but also impact intercellular and interorgan interplays whose importance to control liver functions is further defined. Finally, we highlight the need of considering individual parameters such as sex and disease stage in the development of NR-based clinical strategies.
引用
- Dubois V, Lefebvre P, Staels B, et al. Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease. Gut. 2024. PMID: 38862216. doi:10.1136/gutjnl-2023-331741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。